When Will Mounjaro Be Cheaper in the UK?

What Lilly's 2025 price increase means for the outlook

The most concrete data point on Mounjaro pricing is what has already happened. Eli Lilly raised the UK list price of tirzepatide pens on 1 September 2025. At the top of the dosing schedule, the per-pen cost moved from roughly £122 to roughly £330. That is not a rounding error, it is a structural reset of what private treatment costs in this country, and it has pushed monthly spend at higher doses well above £300 for many patients.

For a price reduction to follow, one of three things would need to happen: Lilly reverses course (no indication of this), a competitor biosimilar reaches the UK market (tirzepatide's patent protection runs for years yet), or NHS commissioning scales up enough to reduce private demand. None of those look imminent. Our detailed analysis of whether Mounjaro will get cheaper sets out the patent timeline in full.

NICE's appraisal of tirzepatide, TA1026 published December 2024, recommends it within the NHS for a phased, tightly defined population. That rollout is real, but it affects NHS eligibility, not private list prices. The two markets move independently.

Why the NHS rollout probably won't bring private prices down soon

There is a reasonable theory that broader NHS prescribing will eventually create scale economies that filter through to private pricing. In practice that transmission is slow and uncertain. The NHS phases are narrow: Cohort 1 (from June 2025) requires a BMI of 40 or above plus four or more qualifying conditions; Cohort 2, activated in June 2026, extends to BMI 35–39.9 with four or more conditions. Most people currently paying privately sit outside those thresholds or simply cannot access a qualifying service near them.

Until biosimilar manufacturers complete regulatory approval (a process that typically takes years after patent expiry) the originator brand controls pricing. The longer-term question of whether Mounjaro will ever be cheaper is worth reading if you are planning treatment over a multi-year horizon, but the honest short answer is: not within the next couple of years.

What can shift in the nearer term is the composition of what you pay for. Some providers charge separately for consultations, prescriptions and delivery. Others bundle them. That difference is more immediate and more within your control than waiting for a market-wide price drop.

What a headline price does and doesn't include

When you see a monthly figure quoted for Mounjaro, check what it covers. A consultation fee is often separate (sometimes £30–£70) and is charged whether or not treatment is approved. Delivery charges vary; some providers charge per shipment. Aftercare, dose-review calls and clinical re-checks before each repeat are not always included and can add up quietly over time.

The pen itself sitting in your fridge between doses is only one part of the cost of being safely on treatment, and if you are unsure how much Mounjaro you inject at each stage of the dosing schedule, that affects how far each pen goes and therefore what you pay per month. The question of where Mounjaro is genuinely cheaper (once you account for everything) is often different from what headline prices suggest.

At nume, one price covers the consultation, prescription, treatment, delivery and aftercare. We are not the cheapest option in the market and we are straightforward about that. What the single price buys is a GPhC-registered pharmacy, a prescriber who reviews your case personally before every order, and next-working-day DPD delivery once approved. There are no subscription traps; every repeat is reviewed as a fresh clinical decision. You can read more about how we work if you want the detail.

Why price is the wrong measure for a prescription medicine

It is worth saying plainly: for a POM, the right question is not who is cheapest but whether the supply chain is legitimate and the prescribing is safe. The MHRA has warned publicly (and backed that warning with enforcement) that counterfeit tirzepatide pens are circulating in the UK. In October 2025, officers raided an illicit manufacturing site in Northampton producing fake pens; earlier seizures across 2025 recovered around 20 million doses with a street value of roughly £45m. The pattern is consistent: the cheapest listings, the social-media sellers, the sites offering treatment without a clinical assessment are where the risk concentrates.

Any legitimate pharmacy can be verified on the GPhC register. A seller offering Mounjaro at prices far below the reported market range, or without requiring a prescriber review, is a red flag worth taking seriously. The MHRA's Yellow Card scheme accepts reports of suspect sellers alongside reports of side effects.

If you would like to understand exactly when Mounjaro prices might fall, or want to explore whether a cheaper equivalent exists in the UK, those pages set out the position clearly. If you are also trying to plan your budget around the dosing schedule, our guide covering when Mounjaro prices will go up explains what further increases could look like and when they might arrive. When you are ready to start, our prescribers are available for a free consultation, and if you are approved before noon on a working day, your treatment ships the same day.